Pharma Equity Group Company Description

Pharma Equity Group A/S, through its subsidiary, Reponex Pharmaceuticals A/S, a clinical-stage biopharmaceutical company, develops treatments for diseases that have patient and social impact for which current therapy is lacking or in need of improvement.

Its products under development that are in Phase II clinical trials include RNX-011 for the treatment of bacterial peritonitis; RNX-021, RNX-022, and RNX-023 for the treatment of Ulcus Cruris chronic skin ulcers; RNX-041 for the treatment of inflammatory bowel diseases, such as chrons and pouchitis; and RNX-051 for the treatment of colorectal cancer and colon adenoma.

The company was incorporated in 2002 and is headquartered in Horsholm, Denmark.

Pharma Equity Group A/S

Country	Denmark
Founded	2002
Industry	Biotechnology
Sector	Healthcare
Employees	1
CEO	Christian Tange

Contact Details

Address: Slotsmarken 18 2. th. Horsholm, 2970 Denmark
Phone	45 41 92 25 25
Website	pharmaequitygroup.com

Stock Details

Ticker Symbol	PEG
Exchange	Copenhagen Stock Exchange
Fiscal Year	January - December
Reporting Currency	DKK
ISIN Number	DK0061155009
SIC Code	6799

Key Executives

Name	Position
Sebastian Bo Jakobsen	Chief Executive Officer of Reponex Pharmaceuticals
Christian Henrik Tange	Chief Executive Officer
Peter Ekman	Financial Manager
Lars Skriver	Chief Operations Officer
Pernille Lyngholm	Chief Business Development Officer
Dr. Lars Otto Uttenthal	Chief Medical Officer